BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19225428)

  • 1. Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy.
    Kim JG; Ku SY; Kim H; Chun SW; Suh CS; Choi YM
    Menopause; 2009; 16(3):534-8. PubMed ID: 19225428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women.
    Kim H; Chun S; Ku SY; Suh CS; Choi YM; Kim JG
    Menopause; 2009; 16(5):1014-20. PubMed ID: 19369902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
    Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
    Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women.
    Kim H; Choe SA; Ku SY; Kim SH; Kim JG
    Menopause; 2011 Jul; 18(7):808-13. PubMed ID: 21471826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy.
    Gür A; Denli A; Nas K; Cevik R; Karakoc M; Sarac AJ; Erdogan F
    Rheumatol Int; 2002 Sep; 22(5):194-8. PubMed ID: 12215865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women.
    Kim JG; Choi YM; Moon SY; Lee JY
    Menopause; 2003; 10(6):544-9. PubMed ID: 14627864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.
    Tziakas D; Chalikias G; Parissis JT; Hatzinikolaou H; Stakos D; Papadopoulou E; Kortsaris A; Hatseras D
    Eur Cytokine Netw; 2004; 15(3):231-9. PubMed ID: 15542448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type D personality is associated with increased levels of tumour necrosis factor (TNF)-alpha and TNF-alpha receptors in chronic heart failure.
    Conraads VM; Denollet J; De Clerck LS; Stevens WJ; Bridts C; Vrints CJ
    Int J Cardiol; 2006 Oct; 113(1):34-8. PubMed ID: 16325284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between estrogens and serum adipocytokines in premenopausal and postmenopausal women.
    Hong SC; Yoo SW; Cho GJ; Kim T; Hur JY; Park YK; Lee KW; Kim SH
    Menopause; 2007; 14(5):835-40. PubMed ID: 17667144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum levels of solubule tumor necrosis factor (TNF) receptors in patients with pulmonary tuberculosis].
    Kawaguchi H; Ina Y; Ito S; Sato S; Sugiura Y; Tomita H; Ogisu N; Takada K; Yamamoto M; Morishita M; Yoshikawa K
    Kekkaku; 1996 Mar; 71(3):259-65. PubMed ID: 8901228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal evaluation of serum leptin and bone mineral density in early postmenopausal women.
    Di Carlo C; Tommaselli GA; Di Spiezio Sardo A; Sammartino A; Attianese W; Gargano V; Bifulco G; Nappi C
    Menopause; 2007; 14(3 Pt 1):450-4. PubMed ID: 17242633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.
    Song EK; Yeom JH; Shin HT; Kim SH; Shin WG; Oh JM
    J Clin Pharm Ther; 2006 Oct; 31(5):421-7. PubMed ID: 16958819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in profiles of circulating insulin-like growth factor components during hormone replacement therapy according to the responsiveness to therapy in postmenopausal women.
    Kim JG; Lee JY
    Am J Obstet Gynecol; 2001 May; 184(6):1139-44. PubMed ID: 11349179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor necrosis factor alpha is higher in non-obese, non-diabetic Mexican Americans compared to non-Hispanic white adults.
    Ho RC; Davy KP; Hickey MS; Melby CL
    Cytokine; 2005 Apr; 30(1):14-21. PubMed ID: 15784408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.